Violacein induces p44/42 mitogen-activated protein kinase‑mediated solid tumor cell death and inhibits tumor cell migration

Mehta,Toral; Vercruysse,Koen; Johnson,Terrance; Ejiofor,Anthony Okechukwu; Myles,Elbert; Quick,Quincy Antoine

doi:10.3892/mmr.2015.3525

Violacein induces p44/42 mitogen-activated protein kinase‑mediated solid tumor cell death and inhibits tumor cell migration

Authors:
- Toral Mehta
- Koen Vercruysse
- Terrance Johnson
- Anthony Okechukwu Ejiofor
- Elbert Myles
- Quincy Antoine Quick
View Affiliations

Affiliations: Department of Biological Sciences, Tennessee State University, Nashville, TN 37209, USA, Department of Chemistry, Tennessee State University, Nashville, TN 37209, USA
Published online on: March 20, 2015 https://doi.org/10.3892/mmr.2015.3525
Pages: 1443-1448

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Microbial secondary metabolites have emerged as alternative novel drugs for the treatment of human cancers. Violacein, a purple pigment produced by Chromobacterium violaceum, was investigated in the present study for its anti‑tumor properties in tumor cell lines. Clinically applicable concentrations of violacein were demonstrated to inhibit the proliferative capacity of tumor cell lines according to a crystal violet proliferation assay. The underlying mechanism was the promotion of apoptotic cell death, as indicated by poly(ADP ribose) polymerase cleavage and p44/42 mitogen‑activated protein kinase signaling determined by western blot analysis. Collectively, this provided mechanistic evidence that violacein elicits extracellular-signal regulated kinase‑induced apoptosis via the intrinsic pathway. The anti‑malignant properties of violacein in the present study were further demonstrated by its inhibitory effects on brain tumor cell migration, specifically glioblastomas, one of the most invasive and therapeutically resistant neoplasms in the clinic. Additionally, solid tumors examined in the present study displayed differential cellular responses and sensitivities to violacein as observed by morphologically induced cellular changes that contributed to its anti‑migratory properties. In conclusion, violacein is a novel natural product with the potential to kill several types of human tumor cell lines, as well as prevent disease recurrence by antagonizing cellular processes that contribute to metastatic invasion.

View Figures

View References

1	Forbes NS: Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer. 10:785–794. 2010. View Article : Google Scholar : PubMed/NCBI
2	Patyar S, Joshi R, Byrav DS, Prakash A, Medhi B and Das BK: Bacteria in cancer therapy: A novel experimental strategy. J Biomed Sci. 17:212010. View Article : Google Scholar : PubMed/NCBI
3	Bernardes N, Seruca R, Chakrabarty AM and Fialho AM: Microbial-based therapy of cancer: Current progress and future prospects. Bioeng Bugs. 1:178–190. 2010. View Article : Google Scholar
4	Andrighetti-Fröhner CR, Antonio RV, Creczynski-Pasa TB, Barardi CR and Simões CM: Cytotoxicity and potential antiviral evaluation of violacein produced by Chromobacterium violaceum. Mem Inst Oswaldo Cruz. 98:843–848. 2003. View Article : Google Scholar : PubMed/NCBI
5	Vaishnav P and Demain AL: Unexpected applications of secondary metabolites. Biotechnol Adv. 29:223–229. 2011. View Article : Google Scholar
6	Ito T, Kawata S, Tamura S, Igura T, Nagase T, Miyagawa JI, Yamazaki E, Ishiguro H and Matasuzawa Y: Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor. Jpn J Cancer Res. 87:113–116. 1996. View Article : Google Scholar : PubMed/NCBI
7	Kainuma O, Asano T, Hasegawa M, Kenmochi T, Nakagohri T, Tokoro Y and Isono K: Inhibition of growth and invasive activity of human pancreatic cancer cells by a farnesyltransferase inhibitor, manumycin. Pancreas. 15:379–383. 1997. View Article : Google Scholar : PubMed/NCBI
8	Yeung SC, Xu G, Pan J, Christgen M and Bamiagis A: Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res. 60:650–656. 2000.PubMed/NCBI
9	She M, Pan I, Sun L and Yeung SC: Enhancement of manumycin A-induced apoptosis by methoxyamine in myeloid leukemia cells. Leukemia. 19:595–602. 2005.PubMed/NCBI
10	Frassanito MA, Cusmai A, Piccoli C and Dammacco F: Manumycin inhibits farnesyltransferase and induces apoptosis of drug-resistant interleukin 6-producing myeloma cells. Br J Haematol. 118:157–165. 2002. View Article : Google Scholar : PubMed/NCBI
11	Zhou JM, Zhu XF, Pan QC, Liao DF, Li ZM and Liu ZC: Manumycin inhibits cell proliferation and the Ras signal transduction pathway in human hepatocellular carcinoma cells. Int J Mol Med. 11:767–771. 2003.PubMed/NCBI
12	Zhou JM, Zhu XF, Pan QC, Liao DF, Li ZM and Liu ZC: Manumycin induces apoptosis in human hepatocellular carcinoma HepG2 cells. Int J Mol Med. 12:955–959. 2003.PubMed/NCBI
13	Pan J, Xu G and Yeung SC: Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J Clin Endocrinol Metab. 86:4731–4740. 2001. View Article : Google Scholar : PubMed/NCBI
14	Ishii T, Hayashi K, Hida T, Yamamoto Y and Nozaki Y: TAN-1813, a novel Ras-farnesyltransferase inhibitor produced by Phoma sp. taxonomy, fermentation, isolation and biological activities in vitro and in vivo. J Antibiot (Tokyo). 53:765–778. 2000. View Article : Google Scholar
15	Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Bélec L, Billot X, et al: Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA. 104:19512–19517. 2007. View Article : Google Scholar : PubMed/NCBI
16	Pérez-Galán P, Roué G, Villamor N, Campo E and Colomer D: The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood. 109:4441–4449. 2007. View Article : Google Scholar : PubMed/NCBI
17	Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY and Stewart AK: Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood. 109:5430–5438. 2007. View Article : Google Scholar : PubMed/NCBI
18	Fumoleau P, Coudert B, Isambert N and Ferrant E: Novel tubulin-targeting agents: Anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 18(Suppl 5): v9–v15. 2007. View Article : Google Scholar : PubMed/NCBI
19	Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP and Downing KH: The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science. 305:866–869. 2004. View Article : Google Scholar : PubMed/NCBI
20	Cheng KL, Bradley T and Budman DR: Novel microtubule-targeting agents - the epothilones. Biologics. 2:789–811. 2008.
21	Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E and Woods CM: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55:2325–2333. 1995.PubMed/NCBI
22	Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC and Kramer RA: BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 7:1429–1437. 2001.PubMed/NCBI
23	de Carvalho DD, Costa FT, Duran N and Haun M: Cytotoxic activity of violacein in human colon cancer cells. Toxicol In Vitro. 20:1514–1521. 2006. View Article : Google Scholar : PubMed/NCBI
24	Kodach LL, Bos CL, Durán N, Peppelenbosch MP, Ferreira CV and Hardwick JC: Violacein synergistically increases 5-fluoro-uracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. Carcinogenesis. 27:508–516. 2006. View Article : Google Scholar
25	Queiroz KC, Milani R, Ruela-de-Sousa RR, Fuhler GM, Justo GZ, Zambuzzi WF, Duran N, Diks SH, Spek CA, Ferreira CV, et al: Violacein induces death of resistant leukaemia cells via kinome reprogramming, endoplasmic reticulum stress and Golgi apparatus collapse. PLoS One. 7:e453622012. View Article : Google Scholar : PubMed/NCBI
26	Melo PS, Justo GZ, de Azevedo MB, Durán N and Haun M: Violacein and its beta-cyclodextrin complexes induce apoptosis and differentiation in HL60 cells. Toxicology. 186:217–225. 2003. View Article : Google Scholar : PubMed/NCBI
27	Ferreira CV, Bos CL, Versteeg HH, Justo GZ, Durán N and Peppelenbosch MP: Molecular mechanism of violacein-mediated human leukemia cell death. Blood. 104:1459–1464. 2004. View Article : Google Scholar : PubMed/NCBI
28	Bromberg N, Dreyfuss JL, Regatieri CV, Palladino MV, Durán N, Nader HB, Haun M and Justo GZ: Growth inhibition and pro-apoptotic activity of violacein in Ehrlich ascites tumor. Chem Biol Interact. 186:43–52. 2010. View Article : Google Scholar : PubMed/NCBI
29	Rettori D and Durán N: Production, extraction and purification of violacein: an antibiotic pigment produced by Chromobacterium violaceum. World Journal of Microbiology and Biotechnology. 4:685–688. 1998. View Article : Google Scholar
30	Stelzer KJ: Epidemiology and prognosis of brain metastases. Surg Neurol Int. 4(Suppl 4): S192–S202. 2013.PubMed/NCBI
31	Melo PS, De Azevedo MM, Frungillo L, Anazetti MC, Marcato PD and Duran N: Nanocytotoxicity: Violacein and violacein-loaded poly (D,L-lactide-co-glycolide) nanoparticles acting on human leukemic cells. J Biomed Nanotechnol. 5:192–201. 2009. View Article : Google Scholar
32	Melo PS, Maria SS, Vidal BC, Haun M and Durán N: Violacein cytotoxicity and induction of apoptosis in V79 cells. In Vitro Cell Dev Biol Anim. 36:539–543. 2000. View Article : Google Scholar
33	Saraiva VS, Marshall JC, Cools-Lartigue J and Burnier MN Jr: Cytotoxic effects of violacein in human uveal melanoma cell lines. Melanoma Res. 14:421–424. 2004. View Article : Google Scholar : PubMed/NCBI
34	Menezes CB, Silva BP, Sousa IM, Ruiz AL, Spindola HM, Cabral E, Eberlin MN, Tinti SV, Carvalho JE, Foglio MA, et al: In vitro and in vivo antitumor activity of crude extracts obtained from Brazilian Chromobacterium sp isolates. Braz J Med Biol Res. 46:65–70. 2013.
35	Mojib N, Nasti TH, Andersen DT, Attigada VR, Hoover RB, Yusuf N and Bej AK: The antiproliferative function of violacein-like purple violet pigment (PVP) from an Antarctic Janthinobacterium sp. Ant5-2 in UV-induced 2237 fibrosarcoma. Int J Dermatol. 50:1223–1233. 2011. View Article : Google Scholar : PubMed/NCBI
36	Platt D, Amara S, Mehta T, Vercuyssee K, Myles EL, Johnson T and Tiriveedhi V: Violacein inhibits matrix metalloproteinase mediated CXCR4 expression: Potential anti-tumor effect in cancer invasion and metastasis. Biochem Biophys Res Commun. 455:107–112. 2014. View Article : Google Scholar : PubMed/NCBI
37	VanderMolen KM, McCulloch W, Pearce CJ and Oberlies NH: Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 64:525–531. 2011. View Article : Google Scholar